Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News GSK walks away from IDEAYA cancer assets: What went wrong with synthetic lethality? GSK ends its partnership with IDEAYA on two oncology assets. Find out what this means for IDEAYA’s pipeline, stock sentiment, and future partnerships. byPallavi MadhirajuDecember 6, 2025